The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...
When my skin is angry and my perioral dermatitis is at its worst, I recommend Avène’s cicalfate+ restorative protective cream ...
Learn why representation in atopic dermatitis clinical trials matters for people of color, as well as the benefits, risks, ...
Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and ...
MedPage Today on MSN
'Incredible' Response Rates in Atopic Dermatitis With Drugs From China
Historically good results with IL-4 inhibitors raise questions with U.S. audience ...
Patients with atopic dermatitis who receive treatment with dupilumab may be at an increased risk for new-onset vitiligo.
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...
As the 2026 American Academy of Dermatology (AAD) annual meeting continues in Denver, MedPage Today is offering another ...
Children with vs without active AD in Denmark had a similar prevalence of nonpassing grades (12.0% vs 11.2%; adjusted ...
HealthDay News — Atopic dermatitis (AD) during childhood is not associated with increases in markers of cardiovascular risk, according to a study published online March 24 in JAMA Network Open.
Patients with seborrheic dermatitis are at an increased risk of developing scarring alopecia compared with those without seborrheic dermatitis.
Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results